Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve deve...Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve development and maturation.Its cleavable extracellular domain(ECD)is readily detectable in various biological fluids including plasma,serum and urine.There is evidence for increased p75NTR ECD levels in neurodegenerative diseases such as Alzheimer’s disease,amyotrophic lateral sclerosis,age-related dementia,schizophrenia,and diabetic neuropathy.Whether p75^(NTR) ECD could be used as a biomarker for diagnosis and/or prognosis in these disorders,and whether it could potentially lead to the development of targeted therapies,remains an open question.In this review,we present and discuss published studies that have evaluated the relevance of this emerging biomarker in the context of various neurodegenerative diseases.We also highlight areas that require further investigation to better understand the role of p75^(NTR) ECD in the clinical diagnosis and management of neurodegenerative disorders.展开更多
目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选...目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选(MACS)法进行p75NTR阳性细胞与阴性细胞的分选,观察p75NTR阳性细胞的增殖、分化及软琼脂克隆形成能力,并进行裸鼠接种以观察其致瘤能力;应用化疗药物作用于ECCs后检测其中p75NTR阳性细胞与阴性细胞存活率,以评价p75NTR阳性细胞对化疗药物的耐受性。结果:8个食管肿瘤细胞系(株)中,除SHEC-1、SHEC-5未检测到p75NTR阳性细胞外,其余6个细胞系(株)SHEC-4、SHEC-6、SHEC-7、SHEC-8、Eca109、TE-1中均检测到p75NTR阳性细胞,阳性细胞比例分别为2.71%、0.32%、3.35%、1.13%、2.15%、0.45%。与阴性及未分选细胞相比,MACS分选后的p75NTR阳性细胞具有较强的增殖能力,具有分化产生其他表型细胞的能力,在软琼脂中具有较强的克隆形成能力(P<0.01);行裸鼠接种时,p75NTR阳性细胞表现出较强的致瘤性,其中SHEC-7细胞只需2×103个即可致瘤,其致瘤能力是未分选细胞的50倍。化疗药物分别作用于p75NTR阳性细胞与阴性细胞48h后,p75NTR阳性细胞的存活比例明显高于阴性细胞(P<0.05)。结论:人食管肿瘤细胞中p75NTR阳性细胞具有自我更新、分化、增殖能力,对化疗药物具有较强的耐受性,并具有较强的致瘤能力,具有肿瘤干细胞的特性。展开更多
目的:探讨钼对食管癌细胞ECA-109化疗敏感性的影响及对食管癌干细胞p75NTR作用.方法:本实验选用人食管癌细胞(esophageal cancer cells,ECCs)ECA-109.设计分为4组:空白对照组、顺铂组、单纯加钼组、顺铂加钼组,后3组均采用不同的浓度进...目的:探讨钼对食管癌细胞ECA-109化疗敏感性的影响及对食管癌干细胞p75NTR作用.方法:本实验选用人食管癌细胞(esophageal cancer cells,ECCs)ECA-109.设计分为4组:空白对照组、顺铂组、单纯加钼组、顺铂加钼组,后3组均采用不同的浓度进行试验.用MTT法检测各组对人食管癌细胞ECA-109的生长抑制作用;流式细胞仪检测各组p75NTR百分率的变化.结果:顺铂组各浓度对食管癌细胞ECA-109有一定的抑制作用,且对食管癌干细胞也有不同程度的抑制作用,并且随着给药浓度和时间的增加均呈增强趋势;单纯加钼组对食管癌细胞ECA-109和对食管癌干细胞的抑制作用均不明显;顺铂加钼组对食管癌细胞ECA-109和食管癌干细胞的抑制作用则明显增强,与单用同浓度顺铂组及空白对照组比较有差异性(P<0.05),且呈一定的浓度、时间依赖性.结论:钼可明显增强顺铂对食管癌细胞ECA-109和食管癌干细胞的抑制作用,而单用钼则达不到理想的效果,说明钼可作为化疗增敏剂,为其作为食管癌化疗的辅助剂提供了实验依据.展开更多
目的:研究子宫内膜异位症(内异症)患者在位内膜神经生长因子(NGF)及其受体trkA、p75NTR的表达,探讨上述因子与内异症疼痛的关系。方法:选择就诊于北京协和医院并进行了腹腔镜手术的28例子宫内膜异位症患者作为研究组,非子宫内膜异位症患...目的:研究子宫内膜异位症(内异症)患者在位内膜神经生长因子(NGF)及其受体trkA、p75NTR的表达,探讨上述因子与内异症疼痛的关系。方法:选择就诊于北京协和医院并进行了腹腔镜手术的28例子宫内膜异位症患者作为研究组,非子宫内膜异位症患者10例作为对照组(B组),收集上述患者分泌期在位子宫内膜。根据患者有无痛经,分为内异症疼痛组(A1组,18例)及内异症非疼痛组(A2组,10例)。采用免疫组化比较各组病灶中NGF及其受体trkA、p75NTR的表达,并分析其与痛经的关系。结果:各组在位内膜腺上皮中NGF的表达显著高于间质(P<0.05);内异症疼痛组腺上皮NGF表达较非疼痛组明显升高(359.9±18.7 vs 201.3±34.3,P<0.05)。p75NTR主要在子宫内膜间质细胞中表达;内异症组明显高于非内异症组(58.8±21.1、22.5±16.1 vs 0,P<0.05);内异症疼痛组较非疼痛组p75NTR表达明显升高(58.8±21.1 vs 22.5±16.1,P<0.05)。trkA在非内异症组子宫内膜间质中表达明显高于腺上皮(P<0.05);在内异症组腺上皮中,trkA的表达较非内异症组明显增高(P<0.05);trkA的表达量与内异症患者疼痛无关。结论:p75NTR可能参与内异症的发病,NGF及其受体p75NTR在在位内膜中的表达与患者疼痛相关,表明其可能参与了内异症疼痛发病机制。展开更多
文摘Neurodegenerative diseases are often misdiagnosed,especially when the diagnosis is based solely on clinical symptoms.The p75 neurotrophic receptor(p75^(NTR))has been studied as an index of sensory and motor nerve development and maturation.Its cleavable extracellular domain(ECD)is readily detectable in various biological fluids including plasma,serum and urine.There is evidence for increased p75NTR ECD levels in neurodegenerative diseases such as Alzheimer’s disease,amyotrophic lateral sclerosis,age-related dementia,schizophrenia,and diabetic neuropathy.Whether p75^(NTR) ECD could be used as a biomarker for diagnosis and/or prognosis in these disorders,and whether it could potentially lead to the development of targeted therapies,remains an open question.In this review,we present and discuss published studies that have evaluated the relevance of this emerging biomarker in the context of various neurodegenerative diseases.We also highlight areas that require further investigation to better understand the role of p75^(NTR) ECD in the clinical diagnosis and management of neurodegenerative disorders.
文摘目的:应用p75NTR进行人食管肿瘤干细胞的分选,并对其生物学特性进行鉴定。方法:对人食管癌标本癌细胞及食管癌细胞株TE-1、Eca109进行培养,应用流式细胞仪检测p75NTR在人食管癌细胞(esophageal cancer cells,ECCs)中的表达,应用磁珠分选(MACS)法进行p75NTR阳性细胞与阴性细胞的分选,观察p75NTR阳性细胞的增殖、分化及软琼脂克隆形成能力,并进行裸鼠接种以观察其致瘤能力;应用化疗药物作用于ECCs后检测其中p75NTR阳性细胞与阴性细胞存活率,以评价p75NTR阳性细胞对化疗药物的耐受性。结果:8个食管肿瘤细胞系(株)中,除SHEC-1、SHEC-5未检测到p75NTR阳性细胞外,其余6个细胞系(株)SHEC-4、SHEC-6、SHEC-7、SHEC-8、Eca109、TE-1中均检测到p75NTR阳性细胞,阳性细胞比例分别为2.71%、0.32%、3.35%、1.13%、2.15%、0.45%。与阴性及未分选细胞相比,MACS分选后的p75NTR阳性细胞具有较强的增殖能力,具有分化产生其他表型细胞的能力,在软琼脂中具有较强的克隆形成能力(P<0.01);行裸鼠接种时,p75NTR阳性细胞表现出较强的致瘤性,其中SHEC-7细胞只需2×103个即可致瘤,其致瘤能力是未分选细胞的50倍。化疗药物分别作用于p75NTR阳性细胞与阴性细胞48h后,p75NTR阳性细胞的存活比例明显高于阴性细胞(P<0.05)。结论:人食管肿瘤细胞中p75NTR阳性细胞具有自我更新、分化、增殖能力,对化疗药物具有较强的耐受性,并具有较强的致瘤能力,具有肿瘤干细胞的特性。
文摘目的:探讨钼对食管癌细胞ECA-109化疗敏感性的影响及对食管癌干细胞p75NTR作用.方法:本实验选用人食管癌细胞(esophageal cancer cells,ECCs)ECA-109.设计分为4组:空白对照组、顺铂组、单纯加钼组、顺铂加钼组,后3组均采用不同的浓度进行试验.用MTT法检测各组对人食管癌细胞ECA-109的生长抑制作用;流式细胞仪检测各组p75NTR百分率的变化.结果:顺铂组各浓度对食管癌细胞ECA-109有一定的抑制作用,且对食管癌干细胞也有不同程度的抑制作用,并且随着给药浓度和时间的增加均呈增强趋势;单纯加钼组对食管癌细胞ECA-109和对食管癌干细胞的抑制作用均不明显;顺铂加钼组对食管癌细胞ECA-109和食管癌干细胞的抑制作用则明显增强,与单用同浓度顺铂组及空白对照组比较有差异性(P<0.05),且呈一定的浓度、时间依赖性.结论:钼可明显增强顺铂对食管癌细胞ECA-109和食管癌干细胞的抑制作用,而单用钼则达不到理想的效果,说明钼可作为化疗增敏剂,为其作为食管癌化疗的辅助剂提供了实验依据.
文摘目的:研究子宫内膜异位症(内异症)患者在位内膜神经生长因子(NGF)及其受体trkA、p75NTR的表达,探讨上述因子与内异症疼痛的关系。方法:选择就诊于北京协和医院并进行了腹腔镜手术的28例子宫内膜异位症患者作为研究组,非子宫内膜异位症患者10例作为对照组(B组),收集上述患者分泌期在位子宫内膜。根据患者有无痛经,分为内异症疼痛组(A1组,18例)及内异症非疼痛组(A2组,10例)。采用免疫组化比较各组病灶中NGF及其受体trkA、p75NTR的表达,并分析其与痛经的关系。结果:各组在位内膜腺上皮中NGF的表达显著高于间质(P<0.05);内异症疼痛组腺上皮NGF表达较非疼痛组明显升高(359.9±18.7 vs 201.3±34.3,P<0.05)。p75NTR主要在子宫内膜间质细胞中表达;内异症组明显高于非内异症组(58.8±21.1、22.5±16.1 vs 0,P<0.05);内异症疼痛组较非疼痛组p75NTR表达明显升高(58.8±21.1 vs 22.5±16.1,P<0.05)。trkA在非内异症组子宫内膜间质中表达明显高于腺上皮(P<0.05);在内异症组腺上皮中,trkA的表达较非内异症组明显增高(P<0.05);trkA的表达量与内异症患者疼痛无关。结论:p75NTR可能参与内异症的发病,NGF及其受体p75NTR在在位内膜中的表达与患者疼痛相关,表明其可能参与了内异症疼痛发病机制。